Inspire Medical Systems (NYSE:INSP) Stock Gets Price Target Cut from Barclays

Inspire Medical Systems (NYSE:INSP) had its price objective cut by equities research analysts at Barclays from $65.00 to $62.00 in a research note issued to investors on Tuesday, Benzinga reports. The brokerage currently has an “underweight” rating on the stock. Barclays‘s price objective suggests a potential downside of 0.87% from the company’s current price.

Several other analysts also recently weighed in on the stock. Oppenheimer upgraded shares of Inspire Medical Systems from a “market perform” rating to an “outperform” rating and set a $85.00 price objective for the company in a research report on Tuesday, August 4th. Piper Sandler increased their target price on shares of Inspire Medical Systems from $60.00 to $70.00 and gave the company a “neutral” rating in a research report on Tuesday. Truist Financial set a $76.00 price target on shares of Inspire Medical Systems in a research note on Tuesday. Evercore set a $54.00 price target on shares of Inspire Medical Systems in a research report on Tuesday, August 4th. Finally, Mizuho set a $75.00 price objective on shares of Inspire Medical Systems in a research note on Tuesday, October 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $70.94.

Inspire Medical Systems Price Performance

Shares of NYSE INSP traded down $4.66 during midday trading on Tuesday, hitting $62.55. 94,749 shares of the company’s stock were exchanged, compared to its average volume of 1,040,750. Inspire Medical Systems has a twelve month low of $38.91 and a twelve month high of $147.03. The company has a market cap of $1.81 billion, a PE ratio of 13.53, a P/E/G ratio of 5.37 and a beta of 0.73. The firm’s fifty day simple moving average is $68.69 and its 200-day simple moving average is $58.82.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings results on Monday, November 2nd. The company reported $0.14 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.09 by $0.05. The firm had revenue of $206.69 million during the quarter, compared to the consensus estimate of $204.31 million. Inspire Medical Systems had a return on equity of 8.64% and a net margin of 15.03%. The firm’s quarterly revenue was down 7.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.38 earnings per share. Equities analysts anticipate that Inspire Medical Systems will post 1.24 EPS for the current fiscal year.

Insider Activity

In other news, insider Jason Kelly sold 963 shares of the firm’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $59.55, for a total transaction of $57,346.65. Following the transaction, the insider directly owned 18,985 shares in the company, valued at approximately $1,130,556.75. This trade represents a 4.83% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 2.20% of the company’s stock.

Institutional Trading of Inspire Medical Systems

Several institutional investors and hedge funds have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in Inspire Medical Systems during the 2nd quarter worth $211,341,000. ADAR1 Capital Management LLC increased its stake in Inspire Medical Systems by 2,601.3% in the first quarter. ADAR1 Capital Management LLC now owns 405,197 shares of the company’s stock valued at $20,900,000 after purchasing an additional 390,197 shares during the period. Assenagon Asset Management S.A. raised its holdings in shares of Inspire Medical Systems by 66.2% in the second quarter. Assenagon Asset Management S.A. now owns 864,395 shares of the company’s stock valued at $38,561,000 after buying an additional 344,221 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in shares of Inspire Medical Systems in the second quarter valued at about $12,021,235. Finally, Bank of America Corp DE purchased a new stake in shares of Inspire Medical Systems in the second quarter valued at about $11,099,000. Hedge funds and other institutional investors own 94.91% of the company’s stock.

Trending Headlines about Inspire Medical Systems

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Inspire reported third-quarter adjusted EPS of $0.14, ahead of the $0.09 consensus estimate, while revenue of approximately $206.7 million exceeded expectations of $204.3 million. Inspire Medical Systems Announces Third Quarter 2026 Financial Results
• Positive Sentiment: The company’s fiscal 2026 guidance has a midpoint of $1.30 for EPS and $855 million for revenue, modestly above consensus estimates of $1.25 and $853.6 million, respectively. This suggests execution is holding up despite reimbursement-related pressure.
• Positive Sentiment: Robert W. Baird raised its price target from $73 to $77, and Piper Sandler lifted its target from $60 to $70. Both firms retained neutral ratings, indicating improved valuation expectations but limited conviction in a stronger near-term recovery.
• Neutral Sentiment: Management said reimbursement and coding conditions are stabilizing and projected low-single-digit revenue growth for 2027. Stabilization reduces a major business risk, but the expected growth rate remains modest.
• Negative Sentiment: Third-quarter revenue declined 7.9% from the prior year, and EPS fell from $0.38 to $0.14. The results beat reduced expectations but still reflect weaker underlying growth and profitability.
• Negative Sentiment: The neutral analyst ratings and low-single-digit 2027 growth forecast may limit enthusiasm, particularly after Inspire’s shares have already rebounded substantially from their 52-week low.

About Inspire Medical Systems

Inspire Medical Systems, Inc develops and commercializes medical devices for the treatment of obstructive sleep apnea (OSA), a condition in which the upper airway repeatedly narrows or becomes blocked during sleep. The company’s primary product is Inspire therapy, an implantable system designed to help keep the airway open by stimulating the hypoglossal nerve, which controls muscles involved in maintaining airway patency.

Inspire therapy is intended for certain adults with moderate to severe OSA who are unable to use or obtain consistent benefit from continuous positive airway pressure (CPAP) therapy.